Among the genetically confirmed patients, DMD (60% n = 83/138), SMA type 0 - type II, and HD patients are identified as eligible to be considered for available gene therapy trials based on their mutation pattern (Table 5). The gene discussed is SMN1; the disease is Huntington disease.